Scientists in South Korea have engineered a new type of cancer-targeting antibody that could dramatically expand the reach of immunotherapy to millions of patients who have been largely excluded from one of modern medicine’s most exciting treatment frontiers. The research, published in the journal Cancer Immunology, Immunotherapy, describes the development and laboratory validation of a bispecific T-cell–engaging antibody that recognizes a peptide-HLA complex found on the surface of cancer cells but absent from nearly all healthy tissues. The work, led by Mooyoung Jung of Ewha Womans University in collaboration with researchers at Curocell Inc. and corresponding author Hyunbo Shim, addresses a long-standing blind spot in targeted cancer immunotherapy: the overwhelming focus of the field on a single immune genotype that represents only a fraction of the world’s population.
The central achievement of the study is a bispecific TCR-like antibody, designated 2F7, which recognizes a fragment of the PRAME protein displayed on the cell surface by the HLA-A*24:02 molecule. To appreciate why this matters, it helps to understand how the immune system inspects cells for danger. Inside virtually every nucleated cell, proteins are constantly being chopped into short peptide fragments by the cellular machinery. A sample of these fragments is loaded onto major histocompatibility complex class I molecules and transported to the cell surface, where they are displayed to patrolling cytotoxic T lymphocytes. In a healthy cell, the peptides are ordinary self-proteins and are ignored. In a cancerous or infected cell, peptides derived from abnormal proteins betray the cell’s true identity, triggering a lethal immune attack.
The catch is that T cells cannot see inside a cell. They only recognize peptides when they are presented in the groove of an HLA molecule, and they do so using highly specialized receptors known as T cell receptors, or TCRs. For decades, immunologists have dreamed of harnessing this recognition system with antibodies — molecules that can be engineered with exquisite specificity, manufactured at scale, and deployed as drugs. This is the rationale behind TCR-like antibodies: artificial binding proteins generated in the laboratory that mimic the specificity of a natural T cell receptor by recognizing a specific peptide-MHC complex. Because they can distinguish a single peptide antigen presented on an HLA scaffold, TCR-like antibodies effectively give therapeutic agents X-ray vision into the interior of a cell, allowing them to target proteins that were previously considered undruggable precisely because they are buried inside the tumor cell and never appear on the surface in conventional form.
Yet almost all TCR-like antibodies developed to date have targeted peptides presented by HLA-A02:01, better known as HLA-A2. This allele is indeed the most common MHC class I variant in the world, but its dominance in the scientific literature reflects convenience as much as biology. HLA genes are among the most polymorphic in the human genome, and peptide presentation is strictly allele-dependent: a given peptide will only be displayed if the individual carries a compatible HLA molecule. A TCR-like antibody built against HLA-A2 presented peptides is therefore useless in patients who do not carry that allele. With HLA-A2 present in only about half of people of European descent and substantially lower proportions in many other populations, entire regions of the world have effectively been locked out of this therapeutic strategy. East Asian populations in particular carry a different dominant allele: HLA-A24:02, the second most frequent MHC class I allele worldwide and the single most common one across much of Asia.
The Korean team chose their target accordingly, and their choice of antigen was equally deliberate. PRAME — preferentially expressed antigen in melanoma — belongs to the cancer-testis antigen family, a class of proteins whose expression is normally restricted to the male germline but which become aberrantly reactivated in a wide spectrum of malignancies. Because healthy adult tissues outside the testes do not produce PRAME, and because the testes are an immunologically privileged site that does not present class I peptides to the immune system in the usual way, a therapy targeting PRAME-derived peptides carries an inherently favorable safety profile. PRAME is expressed in melanoma, lung cancer, breast cancer, leukemia, head and neck cancers, and numerous other tumor types, making it one of the most broadly applicable tumor-associated antigens known. The specific peptide targeted in this study, PRAME301–309, is a nine-amino-acid fragment of the protein presented by HLA-A*24:02.
Finding an antibody that can recognize such a structure is no small feat. Peptide-HLA complexes are notoriously difficult targets: the HLA molecule itself is present on every cell in the body, so the antibody must bind in a way that contacts the specific peptide nestled in the HLA groove while tolerating or ignoring the surrounding HLA framework. The researchers accomplished this using phage display, a powerful in vitro evolution technique in which billions of antibody fragments are displayed on the surface of bacteriophages — viruses that infect bacteria — and screened iteratively for the rare clones that bind the desired target. From this molecular haystack, the team isolated a single-chain variable fragment, or scFv, designated 2F7, specific for the PRAME301–309/HLA-A*24:02 complex.
An scFv, however, is only a building block. To convert it into a therapeutic molecule, the researchers reformatted 2F7 into a bispecific T-cell–engaging antibody, commonly abbreviated as a T-cell engager or bsTLA in this context. Bispecific antibodies are engineered proteins with two different binding arms: one arm recognizes the tumor-associated target — in this case, the PRAME301–309/HLA-A24 complex — while the other arm binds CD3, a signaling component of the T cell receptor complex expressed on essentially all T cells. The result is a molecular matchmaker. By physically bridging a cytotoxic T cell to a cancer cell displaying the target peptide-HLA complex, the bispecific antibody forces the immune cell into intimate contact with its prey, triggering activation, release of cytotoxic granules containing perforin and granzymes, and the destruction of the targeted tumor cell. This mechanism effectively commandeers any T cell in the patient’s body, regardless of the natural specificity of its T cell receptor, and redirects it against the tumor.
The team then put 2F7 through its paces in the laboratory. Using human peripheral blood mononuclear cells — PBMCs, the mixed population of immune cells found in circulating blood — together with cancer cell lines engineered or selected to present the PRAME301–309/HLA-A24 complex, the researchers demonstrated two critical properties. First, the 2F7 bispecific antibody bound specifically and selectively to cells displaying the target peptide-HLA complex, confirming that the phage display campaign had genuinely yielded a TCR-like specificity rather than an antibody that merely recognized HLA-A24 regardless of its peptide cargo. This distinction is paramount: an antibody that bound all HLA-A24 molecules indiscriminately would attack every cell in an HLA-A24-positive patient, with catastrophic consequences. Second, and more importantly, the antibody successfully redirected PBMC-derived T cells to kill target cells presenting the peptide-HLA complex, providing proof of concept that the molecule can orchestrate tumor cell killing through endogenous T cells.
The implications of the work extend well beyond a single antibody. Roughly speaking, a therapy built on HLA-A*24:02 could be applicable to the substantial majority of patients in East Asian countries such as Korea, Japan, and China, as well as sizable patient populations elsewhere — a demographic reach that HLA-A2-based approaches simply cannot match. For South Korea, where much of the biotechnology and cell therapy industry is concentrated, the development of an allele-appropriate TCR-like antibody represents a meaningful step toward immunotherapies designed for the patients most likely to use them. It also establishes a template: the same pipeline of phage display selection, peptide-HLA specificity validation, and bispecific reformatting can in principle be applied to other cancer-testis antigens and other HLA alleles, gradually closing the coverage gaps left by an HLA-A2-centric field.
The researchers emphasize that the current study is an in vitro characterization — the experiments were performed with cultured cells and donor-derived immune cells, not in patients. The path from laboratory validation to clinical application involves additional hurdles: confirmation of efficacy and safety in animal models, manufacturing development, regulatory review, and ultimately clinical trials in which questions of dosing, cytokine toxicity, on-target off-tumor effects, and tumor immune evasion will need to be answered. Cytokine release syndrome, the systemic inflammatory reaction that has complicated the clinical use of other T-cell engagers such as blinatumomab, remains a consideration for any molecule that activates T cells systemically. The authors also note that a patent application pertaining to the antibodies reported in the work is in preparation, a familiar marker of translational intent.
Still, the significance of the achievement is hard to overstate. The T-cell engager concept has already proven clinically transformative in hematologic malignancies, but solid tumors and broader patient populations have remained stubbornly difficult targets. TCR-like antibodies such as 2F7 offer a way to bring the precision of T-cell recognition — the ability to see intracellular antigens through the window of peptide-HLA presentation — into an antibody format that can be produced, standardized, and administered off the shelf, without the complexity and cost of engineering a patient’s own cells. By demonstrating that such a molecule can be built against HLA-A*24:02, the most common class I allele in East Asia and the second most common worldwide, the Ewha Womans University team and their collaborators have broadened the addressable patient population for this technology and issued a quiet challenge to the field: immunotherapy for the world cannot be built on one HLA allele alone. As PRAME-expressing tumors account for a substantial share of human cancers, and as HLA-A24 carriers number in the hundreds of millions, the 2F7 antibody may mark the beginning of a more geographically and genetically inclusive era of targeted cancer immunotherapy.
Subject of Research: Development and in vitro characterization of a bispecific TCR-like antibody (2F7) targeting the PRAME301–309/HLA-A*24:02 peptide-MHC complex for cancer immunotherapy
Subject of Research: Cancer
Article Title: Development and in vitro characterization of a bispecific TCR-like antibody targeting the PRAME301–309/HLA-A*24:02 complex for cancer immunotherapy
Article References: Jung, M., Seo, Y. R., Lee, J. H., Lee, Y. H., & Shim, H. (2026). Development and in vitro characterization of a bispecific TCR-like antibody targeting the PRAME301–309/HLA-A*24:02 complex for cancer immunotherapy. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-026-04546-1
Image Credits: AI Generated
DOI: 10.1007/s00262-026-04546-1
Keywords: Bispecific antibody, TCR-like antibody, Cancer-testis antigen, PRAME, Peptide-MHC complex, T-cell engager, HLA-A*24:02, Cancer immunotherapy, Phage display, T cell redirect
Cite Scienmag News
APA MLA Chicago
Nathaniel Bowman. (September 5, 2026). New bispecific TCR-like antibody targets PRAME complex for cancer immunotherapy. Scienmag. https://scienmag.com/new-bispecific-tcr-like-antibody-targets-prame-complex-for-cancer-immunotherapy/
Nathaniel Bowman. “New bispecific TCR-like antibody targets PRAME complex for cancer immunotherapy.” Scienmag, 5 September 2026, https://scienmag.com/new-bispecific-tcr-like-antibody-targets-prame-complex-for-cancer-immunotherapy/. Accessed 5 September 2026.
Nathaniel Bowman. “New bispecific TCR-like antibody targets PRAME complex for cancer immunotherapy.” Scienmag. September 5, 2026. https://scienmag.com/new-bispecific-tcr-like-antibody-targets-prame-complex-for-cancer-immunotherapy/
Copy citation Download RIS
Tags: antibody engineering for cancerbispecific TCR-like antibodycancer cell surface markerscancer immune surveillancecancer immunotherapycancer-targeting antibody developmentexpanding immunotherapy reachHLA-A*24:02 moleculeimmune system recognition of tumor cellsimmunotherapy for diverse patient populationsimmunotherapy for diverse populationsinnovative cancer immunotherapy strategieslaboratory validation of cancer antibodiespeptide presentation in cancer cellspeptide-based cancer targetingPRAME peptide-HLA complexT-cell engaging antibodytargeted cancer immunotherapytargeted cancer treatment
